Saved in:
| Title: | Neurophysiologic Biomarkers in Neuropsychiatric Disorders Etiologic and Treatment Considerations / |
|---|---|
| From: |
edited by Daniel C. Javitt, James C. McPartland.
|
| Person: |
Javitt, Daniel C.
McPartland, James C. editor. |
| Corporate Author: | |
| Other Authors: | , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Cham :
Springer Nature Switzerland : Imprint: Springer,
2024.
|
| Edition: | 1st ed. 2024. |
| Series: | Advances in Neurobiology,
40 |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-3-031-69491-2 |
| Summary: | This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson's disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development. |
| Physical Description: | 1 Online-Ressource (XXIII, 831 p. 146 illus., 127 illus. in color.) |
| ISBN: | 9783031694912 |
| ISSN: | 2190-5223 ; |
Staff View
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | ZDB-2-SBL-978-3-031-69491-2 | ||
| 003 | DE-He213 | ||
| 005 | 20241120115339.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 241120s2024 sz | o |||| 0|eng d | ||
| 020 | |a 9783031694912 |9 978-3-031-69491-2 | ||
| 024 | 7 | |a 10.1007/978-3-031-69491-2 |2 doi | |
| 050 | 4 | |a RC434.2-574 | |
| 072 | 7 | |a MMH |2 bicssc | |
| 072 | 7 | |a MED105000 |2 bisacsh | |
| 072 | 7 | |a MKL |2 thema | |
| 082 | 7 | |a 616.89 |2 23 | |
| 245 | 1 | 0 | |a Neurophysiologic Biomarkers in Neuropsychiatric Disorders |h [electronic resource] : |b Etiologic and Treatment Considerations / |c edited by Daniel C. Javitt, James C. McPartland. |
| 250 | |a 1st ed. 2024. | ||
| 264 | 1 | |a Cham : |b Springer Nature Switzerland : |b Imprint: Springer, |c 2024. | |
| 300 | |a 1 Online-Ressource (XXIII, 831 p. 146 illus., 127 illus. in color.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Advances in Neurobiology, |x 2190-5223 ; |v 40 | |
| 505 | 0 | |a Introduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry - An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson's Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry. | |
| 520 | |a This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson's disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development. | ||
| 650 | 0 | |a Psychiatry. | |
| 650 | 0 | |a Neurosciences. | |
| 650 | 0 | |a Neurology . | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 1 | 4 | |a Psychiatry. |
| 650 | 2 | 4 | |a Neuroscience. |
| 650 | 2 | 4 | |a Neurology. |
| 650 | 2 | 4 | |a Pharmacology. |
| 700 | 1 | |a Javitt, Daniel C. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a McPartland, James C. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031694905 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031694929 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031694936 |
| 830 | 0 | |a Advances in Neurobiology, |x 2190-5223 ; |v 40 | |
| 966 | 4 | 0 | |l DE-355 |p ZDB-2-SBL |q UBG_PDA_SBL |u https://doi.org/10.1007/978-3-031-69491-2 |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||
| 912 | |a ZDB-2-SBL | ||
| 049 | |a DE-355 | ||
Record in the Search Index
| DE-BY-UBR_katkey | ZDB-2-SBL-978-3-031-69491-2 |
|---|---|
| _version_ | 1835726567092781056 |
| adam_text | |
| any_adam_object | |
| author2 | Javitt, Daniel C. McPartland, James C. |
| author2_role | edt edt |
| author2_variant | d c j dc dcj j c m jc jcm |
| author_corporate | SpringerLink (Online service) |
| author_corporate_role | |
| author_facet | Javitt, Daniel C. McPartland, James C. SpringerLink (Online service) |
| building | Verbundindex |
| bvnumber | localUBR |
| callnumber-first | R - Medicine |
| callnumber-label | RC434 |
| callnumber-raw | RC434.2-574 |
| callnumber-search | RC434.2-574 |
| callnumber-sort | RC 3434.2 3574 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-2-SBL ZDB-2-SXB |
| contents | Introduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry - An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson's Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry. |
| dewey-full | 616.89 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.89 |
| dewey-search | 616.89 |
| dewey-sort | 3616.89 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1st ed. 2024. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06035nam a22005535i 4500</leader><controlfield tag="001">ZDB-2-SBL-978-3-031-69491-2</controlfield><controlfield tag="003">DE-He213</controlfield><controlfield tag="005">20241120115339.0</controlfield><controlfield tag="007">cr nn 008mamaa</controlfield><controlfield tag="008">241120s2024 sz | o |||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783031694912</subfield><subfield code="9">978-3-031-69491-2</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-031-69491-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC434.2-574</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MMH</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED105000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MKL</subfield><subfield code="2">thema</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.89</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neurophysiologic Biomarkers in Neuropsychiatric Disorders</subfield><subfield code="h">[electronic resource] :</subfield><subfield code="b">Etiologic and Treatment Considerations /</subfield><subfield code="c">edited by Daniel C. Javitt, James C. McPartland.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2024.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham :</subfield><subfield code="b">Springer Nature Switzerland :</subfield><subfield code="b">Imprint: Springer,</subfield><subfield code="c">2024.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XXIII, 831 p. 146 illus., 127 illus. in color.) </subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="b">PDF</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Advances in Neurobiology,</subfield><subfield code="x">2190-5223 ;</subfield><subfield code="v">40</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Introduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry - An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson's Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson's disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Psychiatry.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Neurosciences.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Neurology .</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmacology.</subfield></datafield><datafield tag="650" ind1="1" ind2="4"><subfield code="a">Psychiatry.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Neuroscience.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Neurology.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Pharmacology.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Javitt, Daniel C.</subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McPartland, James C.</subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">SpringerLink (Online service)</subfield></datafield><datafield tag="773" ind1="0" ind2=" "><subfield code="t">Springer Nature eBook</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783031694905</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783031694929</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783031694936</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Advances in Neurobiology,</subfield><subfield code="x">2190-5223 ;</subfield><subfield code="v">40</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">UBG_PDA_SBL</subfield><subfield code="u">https://doi.org/10.1007/978-3-031-69491-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SXB</subfield></datafield><datafield tag="950" ind1=" " ind2=" "><subfield code="a">Biomedical and Life Sciences (SpringerNature-11642)</subfield></datafield><datafield tag="950" ind1=" " ind2=" "><subfield code="a">Biomedical and Life Sciences (R0) (SpringerNature-43708)</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield></record></collection> |
| id | ZDB-2-SBL-978-3-031-69491-2 |
| illustrated | Not Illustrated |
| indexdate | 2025-06-23T13:27:58Z |
| institution | BVB |
| isbn | 9783031694912 |
| issn | 2190-5223 ; |
| language | English |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XXIII, 831 p. 146 illus., 127 illus. in color.) |
| psigel | ZDB-2-SBL UBG_PDA_SBL ZDB-2-SBL ZDB-2-SXB |
| publishDate | 2024 |
| publishDateSearch | 2024 |
| publishDateSort | 2024 |
| publisher | Springer Nature Switzerland : Imprint: Springer, |
| record_format | marc |
| series | Advances in Neurobiology, |
| series2 | Advances in Neurobiology, |
| spelling | Neurophysiologic Biomarkers in Neuropsychiatric Disorders [electronic resource] : Etiologic and Treatment Considerations / edited by Daniel C. Javitt, James C. McPartland. 1st ed. 2024. Cham : Springer Nature Switzerland : Imprint: Springer, 2024. 1 Online-Ressource (XXIII, 831 p. 146 illus., 127 illus. in color.) text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda Advances in Neurobiology, 2190-5223 ; 40 Introduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry - An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson's Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry. This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson's disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development. Psychiatry. Neurosciences. Neurology . Pharmacology. Neuroscience. Neurology. Javitt, Daniel C. editor. edt http://id.loc.gov/vocabulary/relators/edt McPartland, James C. editor. edt http://id.loc.gov/vocabulary/relators/edt SpringerLink (Online service) Springer Nature eBook Printed edition: 9783031694905 Printed edition: 9783031694929 Printed edition: 9783031694936 |
| spellingShingle | Neurophysiologic Biomarkers in Neuropsychiatric Disorders Etiologic and Treatment Considerations / Advances in Neurobiology, Introduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry - An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson's Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry. Psychiatry. Neurosciences. Neurology . Pharmacology. Neuroscience. Neurology. |
| title | Neurophysiologic Biomarkers in Neuropsychiatric Disorders Etiologic and Treatment Considerations / |
| title_auth | Neurophysiologic Biomarkers in Neuropsychiatric Disorders Etiologic and Treatment Considerations / |
| title_exact_search | Neurophysiologic Biomarkers in Neuropsychiatric Disorders Etiologic and Treatment Considerations / |
| title_full | Neurophysiologic Biomarkers in Neuropsychiatric Disorders [electronic resource] : Etiologic and Treatment Considerations / edited by Daniel C. Javitt, James C. McPartland. |
| title_fullStr | Neurophysiologic Biomarkers in Neuropsychiatric Disorders [electronic resource] : Etiologic and Treatment Considerations / edited by Daniel C. Javitt, James C. McPartland. |
| title_full_unstemmed | Neurophysiologic Biomarkers in Neuropsychiatric Disorders [electronic resource] : Etiologic and Treatment Considerations / edited by Daniel C. Javitt, James C. McPartland. |
| title_short | Neurophysiologic Biomarkers in Neuropsychiatric Disorders |
| title_sort | neurophysiologic biomarkers in neuropsychiatric disorders etiologic and treatment considerations |
| title_sub | Etiologic and Treatment Considerations / |
| topic | Psychiatry. Neurosciences. Neurology . Pharmacology. Neuroscience. Neurology. |
| topic_facet | Psychiatry. Neurosciences. Neurology . Pharmacology. Neuroscience. Neurology. |
| work_keys_str_mv | AT javittdanielc neurophysiologicbiomarkersinneuropsychiatricdisordersetiologicandtreatmentconsiderations AT mcpartlandjamesc neurophysiologicbiomarkersinneuropsychiatricdisordersetiologicandtreatmentconsiderations AT springerlinkonlineservice neurophysiologicbiomarkersinneuropsychiatricdisordersetiologicandtreatmentconsiderations |